CANADA LIFE ASSURANCE Co Has $30.33 Million Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

CANADA LIFE ASSURANCE Co lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 3.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 73,395 shares of the company's stock after acquiring an additional 2,408 shares during the period. CANADA LIFE ASSURANCE Co owned approximately 0.09% of IDEXX Laboratories worth $30,330,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. Canada Pension Plan Investment Board boosted its holdings in shares of IDEXX Laboratories by 12.1% in the 4th quarter. Canada Pension Plan Investment Board now owns 130,100 shares of the company's stock valued at $53,789,000 after purchasing an additional 14,083 shares in the last quarter. GKV Capital Management Co. Inc. bought a new position in IDEXX Laboratories in the fourth quarter valued at about $1,571,000. Foster Dykema Cabot & Partners LLC raised its stake in IDEXX Laboratories by 1,078.7% during the fourth quarter. Foster Dykema Cabot & Partners LLC now owns 884 shares of the company's stock worth $365,000 after acquiring an additional 809 shares in the last quarter. Marshall Wace LLP lifted its holdings in shares of IDEXX Laboratories by 632.6% in the fourth quarter. Marshall Wace LLP now owns 207,114 shares of the company's stock worth $85,629,000 after acquiring an additional 178,841 shares during the last quarter. Finally, NewEdge Advisors LLC boosted its stake in shares of IDEXX Laboratories by 4.8% in the 4th quarter. NewEdge Advisors LLC now owns 11,478 shares of the company's stock valued at $4,745,000 after purchasing an additional 530 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Trading Up 3.4 %

IDXX stock traded up $14.35 during midday trading on Thursday, hitting $440.98. The stock had a trading volume of 746,675 shares, compared to its average volume of 629,776. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The firm has a market cap of $35.74 billion, a P/E ratio of 41.33, a price-to-earnings-growth ratio of 3.41 and a beta of 1.50. The business has a fifty day moving average price of $420.23 and a two-hundred day moving average price of $429.89. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $548.88.

Insider Activity

In other news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares in the company, valued at $1,426,242.34. The trade was a 49.50 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.98% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages recently commented on IDXX. Morgan Stanley dropped their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. StockNews.com downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Saturday, April 12th. Bank of America upped their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Barclays lifted their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Finally, Piper Sandler upped their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research note on Monday, February 10th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $523.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.